Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Stem Cell Transplant with Cyclophosphamide and Radiation in Lymphoma
NCT00004908Phase 2Completed
- Sponsor
- Northwestern University
- Start
- Nov 1999
- Primary completion
- Jun 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide in Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), sponsored by Northwestern University. Primary endpoint: Toxicity of autologous peripheral blood stem cell transplantation regimen at 1 year. Started Nov 1999; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00004908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004908.